Public Health Emergency of International Concern (PHEIC)
Situation report – 208
Coronavirus disease 2019 (COVID-19)
15 August 2020
Confirmed cases :: 21 026 758 [week ago: 19 187 943 ]
Confirmed deaths :: 755 786 [week ago: 716 075]
:: The International Narcotics Control Board, World Health Organization, and the United Nations Office on Drugs and Crime have released a statement calling on governments to ensure that the procurement and supply of controlled medicines in countries meet the needs of patients, both those who have COVID-19 and those who require internationally controlled medicines for other medical conditions.
:: While several countries i n the Americas have implemented innovative strategies to boost immunization programmes during the COVID-19 pandemic, concerns about risk of exposure, as well as challenges accessing services during lockdown, have led to a reduction in vaccination coverage. This was shown in a series of surveys carried out by the WHO Regional Office for the Americas.
:: Africa is marking six months since the first cases of COVID-19 were detected on the continent. Cases have been gradually increasing, with South Africa bearing the brunt of the crisis, with over hal f a mi l lion cases and 11 000 deaths
COVID-19 Vaccines – Access/Procurement/Supply
CEPI reserves manufacturing capacity for COVID-19 vaccines at SK bioscience
13 Aug 2020
:: Vaccine manufacturing capacity in 2020 and 2021 has been reserved for vaccines designated by CEPI.
:: Reserved manufacturing capacity at SK bioscience will support COVAX goal to produce 2 billion doses of safe and effective vaccine by the end of 2021.
August 13 2020, Oslo, Norway– An agreement between CEPI and SK bioscience Co. Ltd. (SK bioscience) has secured capacity to manufacture COVID-19 vaccines at SK bioscience’s facilities in South Korea, supporting the goal of CEPI and its COVAX partners to produce 2 billion doses of safe and effective vaccine by the end of 2021.
Under the terms of the agreement, SK bioscience will reserve manufacturing capacity in 2020 and 2021 exclusively for the development and production of COVID-19 vaccines designated by CEPI. CEPI has an option to extend the reservation of manufacturing capacity beyond 2021, should it be needed…
Trump Administration collaborates with Moderna to produce 100 million doses of COVID-19 investigational vaccine
August 11, 2020
…the U.S. Department of Health and Human Services (HHS) and Department of Defense (DoD) today announced an agreement with Moderna, Inc. to manufacture and deliver 100 million doses of the company’s COVID-19 vaccine candidate. The federal government will own these vaccine doses.
Moderna will manufacture the vaccine doses while clinical trials are underway. Manufacturing in parallel with clinical trials expedites the traditional vaccine development timeline and builds toward the U.S. government’s Operation Warp Speed goal to begin delivering safe and effective vaccines to the American people by the end of the year. If the U.S. Food and Drug Administration (FDA) authorizes use as outlined in agency guidance, the vaccine doses would be distributed and used as part of a COVID-19 vaccination campaign…
Russia receives request for 1 bln COVID-19 vaccine doses from 20 states
Russia is working on an aid program for poor countries to vaccinate against COVID-19, head of the Russian Direct Investment Fund Kirill Dmitriev said
Tass – Russian News Agency
MOSCOW, August 11. /TASS/. Russia has received a request for the production of 1 bln doses of the COVID-19 vaccine produced by the Gamaleya Research Institute of Epidemiology and Microbiology from 20 states, head of the Russian Direct Investment Fund Kirill Dmitriev said during an online conference.
“We see a great interest abroad towards the Russian vaccine produced by the Gamaleya Research Institute. We have received preliminary requests for the purchase of over 1 bln doses of the vaccine from 20 states. We are ready to ensure production of over 500 mln vaccine doses along with our foreign partners in five countries, and we plan to increase our production capacity further,” he stated.
According to Dmitriev, as of today, several Latin American, Middle Eastern and Asian states have expressed an interest in purchasing the Russian vaccine. Several contracts have been finalized.
He noted that the RDIF had agreed to hold the third stage of clinical trials of the COVID-19 vaccine abroad with the UAE, Saudi Arabia and other states.
“The third stage of clinical trials of the Russian vaccine will also take place abroad. We have reached agreements on holding the corresponding trials of the Gamaleya [Research Institute] vaccine with our partners from the UAE, Saudi Arabia and a number of other states,” he informed.
The Russian Direct Investment Fund (RDIF) and partners are working on a humanitarian assistance program for a number of developing countries so that people have equal access to the coronavirus vaccine, Kirill Dmitriev told the conference.
“As we understand that vaccination of the population against coronavirus infection is the most acute issue primarily for the poorest countries, RDIF and partners are working on a humanitarian assistance program for a number of developing states. We believe that people around the world should have equal access to vaccine, regardless of their financial situation, religion, place of residence or other factors, “he said.
On August 11, the Russian Health Ministry registered the first COVID-19 vaccine in the world. The vaccine was developed by the Gamaleya Federal Research Institute of Epidemiology and Microbiology and the Russian Direct Investment Fund.
McKesson to Distribute Future COVID-19 Vaccines in Support of Operation Warp Speed
The Centers for Disease Control is Exercising an Option of an Existing Contract with McKesson for This Effort
August 14, 2020
IRVING, Texas–(BUSINESS WIRE)–A global leader in the healthcare industry, McKesson Corporation (NYSE: MCK) will expand its existing partnership with the Centers for Disease Control (CDC) to support the U.S. government’s Operation Warp Speed (OWS) team as a centralized distributor of future COVID-19 vaccines and ancillary supplies needed to administer vaccinations. Vaccines and related supplies will be delivered to point-of-care sites across the country at the U.S. government’s direction.
“McKesson is committed to supporting public health in the U.S. and around the world,” said Brian Tyler, CEO of McKesson. “Since the onset of the pandemic, McKesson has leveraged our deep expertise to help maintain the integrity of the healthcare supply chain, source and distribute personal protective equipment to frontline workers and stand up COVID-19 testing at Health Mart pharmacies, many in underserved communities. We are honored that the U.S. government has asked McKesson to play a key role in the effort to distribute COVID-19 vaccines.”
The CDC has an existing contract with McKesson to support distribution as part of the CDC’s Vaccines for Children Program (VFC). This contract was awarded to McKesson in a competitive bidding process initiated in 2016 and includes an option for distribution of vaccines in the event of a pandemic. McKesson will utilize its expertise and capabilities, along with other industry partners, to support the CDC’s efforts to vaccinate everyone in the U.S. who wants to receive a COVID-19 vaccine. CDC and McKesson collaborated similarly in response to the H1N1 pandemic.
Beyond programs with the CDC, McKesson is the largest seasonal flu vaccine distributor in the U.S. and distributes up to 150 million doses of all vaccines annually to public health clinics, hospitals, physician offices, nursing homes, pharmacies and other care facilities…